// App-Quantinova.ai

e20588 : A phase I/II study of MLN-8237 (alisertib), an oral aurora kinase inhibitor, in combination with erlotinib in patients with recurrent or metastatic EGFR wild-type non-small cell lung cancer.

Researchers

Presenter

  • James Luke Godwin

Principal Investigators

  • Ranee Mehra

  • Samuel Litwin

  • Anthony J. Olszanski

  • Jessica Ruth Bauman

  • Hossein Borghaei

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Alisertib

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01471964

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved